The scale and impact of background isoniazid resistance in TB-and HIV-endemic countries requires definition to improve treatment success and guide the scale-up of isoniazid preventive therapy (IPT). We describe the effects of isoniazid resistance on TB treatment outcomes among patients with or without HIV infection in Dar es Salaam, Tanzania.
Introduction
TB is the world's leading cause of infectious disease-related mortality, responsible for 1.2-1.5 million global deaths per year.
1,2 MDR and concurrent HIV infection 2 are attributed to increasing TB mortality among TB/HIV-coinfected patients.
TB among HIV patients is a consequence of both reinfections with new mycobacterial strains and/or relapse of previously cured or latent TB infection.
3,4 However, many TB services in subSaharan African countries lack rapid tools for culture and drug resistance testing and hence rely on conventional clinical, radiological or sputum smear microscopy evaluations. 5 Often there is delayed diagnosis, which could possibly complicate therapy or increase the risk of mortality. 6, 7 Monitoring anti-TB resistance in this setting is therefore imperative.
Isoniazid preventive therapy (IPT) is recommended by the WHO for TB prevention among HIV. 8 IPT appears effective in the reduction of incident TB 9 as well as mortality among HIV-infected individuals. 9, 10 However, the implementation complexity of IPT in resource-limited countries presents a potential for isoniazid monotherapy among HIV patients with subclinical TB. 11, 12 Patients with single-drug-resistant TB have been shown to develop MDR-TB with a subsequent TB episode. 13 A previous review showed similar rates of isoniazid resistance in patients with or without HIV infection. 14 However, there is growing evidence that community-wide scaleup of IPT strategies could increase selective pressure that may result in increased isoniazid-resistant TB. 15, 16 It is difficult to quantify trends in isoniazid resistance in most resource-limited settings, where there are dual epidemics of TB and HIV due to lack of systematic mechanisms for isoniazid pharmacovigilance. 17 This, in turn, may affect the implementation and/or evaluation of the IPT policy. Information on isoniazid resistance and its association with TB treatment outcome among both HIV-infected and -uninfected individuals will not only serve as baseline information but also inform policies in similar settings and allow comparison.
A multicentre, prospective observational study was conducted in a cohort of newly diagnosed TB patients initiating anti-TB therapy in Dar es Salaam, Tanzania. We aimed at comparing TB treatment outcomes among patients with and without isoniazid resistance in the absence of MDR-TB.
Methods
This study is part of a larger cohort study aimed at describing factors affecting TB treatment outcomes. Details of the methods were published previously.
18,19

Ethical issues
Ethics permission was granted by the Institutional Review Board of Muhimbili University of Health and Allied Sciences (MUHAS) (reference number MU/DRP/AEC/Vol. XIII/2008). The relevant authorities (municipal directors for health for Ilala, Kindondoni and Temeke, and clinicians in charge of all the participating hospitals) gave permission to interview and follow up the patients. Patients were managed according to the national guidelines for TB management. 20 
Setting
A multicentre prospective cohort study was conducted between October 2010 and December 2011 in Dar es Salaam city, Tanzania. This country has a high burden of TB, recording >60 000 new TB cases every year. 21 Dar es Salaam has the highest rate of TB (311/100 000) in the country. 21 A total of 14 TB clinics (out of 54 TB clinics in the city) participated in the study, inclusive of all three municipalities in Dar es Salaam. The selected clinics had the highest number of TB patients in the city and were selected in order to achieve the required sample size within the study duration.
Patients
TB patients aged !15 years of age who provided a written informed consent and who intended to remain in Dar es Salaam for the entire duration of their TB treatment were included. We excluded all patients with previous use of anti-TB therapy, and those with neither an outcome nor a drug susceptibility pattern.
Procedures
Interviews, clinical evaluation, sputum collection and venepuncture were done by clinicians. Tanzanian national guidelines for TB management were adhered to, which require direct observed therapy (DOT) for a total of 6 months. 20 The intensive phase comprised daily rifampicin at 10 mg/kg, isoniazid at 5 mg/kg, ethambutol at 15 mg/kg and pyrazinamide at 25 mg/kg for 2 months. 20 Patients who attained sputum conversion to smear negative for acid-fast bacilli (AFB) after 2 months of anti-TB continued with daily rifampicin at 10 mg/kg and isoniazid at 5 mg/kg for a further 4 months. 20 Patients who did not attain sputum conversion at 2 months had an extension of the intensive phase by 1 month, after which patients were worked up for possibility of MDR-TB should the sputum still be positive for AFB. At the time of the study, ART was offered to all newly diagnosed HIV-coinfected patients any time between 2 weeks and 2 months after initiation of TB therapy. Sputum microscopy was repeated 2 months after enrolment and treatment outcomes were documented upon completion of anti-TB treatment. 20 
Laboratory investigations
Specimens (sputum and blood) were collected at the clinics in containers pre-labelled with the patient's identification number and initials and were transported to the laboratory in cool pack containers within 2-3 h of collection.
Sputum smears were examined for AFB under direct microscopy following Ziehl-Neelsen (ZN) staining. Results were reported in the patients' request forms and recorded in the laboratory and clinic TB registers.
Sputum culture and drug susceptibility testing (DST) were performed at the Central Reference Tuberculosis Laboratory (CTRL) located at Muhimbili National Hospital using BACTEC Mycobacteria Growth Indicator Tubes (MGIT) (Becton Dickinson) or Löwenstein-Jensen (LJ) media, one supplemented with glycerol (GLJ) and the other with pyruvate (PLJ). Anti-TB drug concentrations used for DST were as follows: 0.2 mg/L for isoniazid, 40 mg/L for rifampicin, 4 mg/L for streptomycin and 2 mg/L for ethambutol. Details of smear microscopy, culture and anti-TB drug-susceptibility testing, including quality assurance, were described in our previous paper. 18 An ACT 5DIFF haematology analyser was used for assessment of haemoglobin and complete blood count according to the manufacturer's instructions (Beckman Coulter, Miami, FL, USA). HIV infection assessment was according to the National HIV screening algorithm, 22 which involved serial testing by Determine HIV-1/2 (Inverness Medical Japan Co. Ltd, Japan) followed Uni-Gold HIV-1/2 (Trinity Biotech, Wicklow, Ireland) for the reactive samples.
Data processing and analysis
Data were captured in case report forms (CRFs) and entered into a database using Epi Info version 6. Analyses were done using the Statistical Program for Social Sciences (SPSS) version 23.
The outcome of interest was TB treatment outcome as a binary variable: successful or unfavourable according to the WHO.
2 Successful treatment includes all TB patients who are cured or for whom treatment is completed without interruption and there is no evidence of treatment failure.
2 An unfavourable TB treatment outcome is considered if there is death due to any cause during the course of anti-TB treatment; if the patient is lost to followup from the clinic for 2 consecutive months, provided the patient has received at least 1 month of TB treatment (loss to follow-up); or if the patient has treatment failure, defined as a sputum smear positive for AFB at the last month of TB treatment. The primary exposure of interest was isoniazid resistance without rifampicin co-resistance. The study population was described using proportions and means/medians for categorical and continuous variables, respectively. Logistic regression was used to assess the association between treatment outcome and isoniazid resistance. Univariate analysis was performed and all factors associated with TB treatment outcome at P < 0.2 were further assessed in a multivariate model. P < 0.05 was considered significant.
Results
Between November 2010 and December 2011, a total of 1365 patients had culture-proven TB (Figure 1 ). Of these, 939 had drugsusceptibility testing performed, six cultures were irreversibly contaminated and 933 were successfully reported. For the purpose of this analysis, we further excluded 72 patients. Two of these had MDR, an established factor associated with poor TB treatment outcomes, and 70 had missing treatment outcomes and were inaccessible after moving out of Dar es Salaam. Table 1 gives details of the basic characteristics of the study group. Overall, the study group had a preponderance of young individuals, with a median age (IQR) of 32 (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) years. There were twice as many males (579, 67.2%) as females. Two hundred and Effects of isoniazid resistance on TB treatment outcomes, Tanzania JAC fifty (29%) patients were HIV infected, out of whom 117 (13.7%) received ART along with TB treatment. A total of 390 (52.1%) of the patients were underweight while 86% were anaemic. In our study cohort, among 231 (27%) who had ever smoked cigarettes, only 47 (5.6%) were current smokers and 184 (21.7%) were past smokers. Table 2 summarizes the isoniazid susceptibility pattern with respect to other first-line anti-TB agents. Among the patients included in this study, 23 (2.7%) had isoniazid resistance. None of the patients with isoniazid resistance had co-existing rifampicin resistance, also known as MDR-TB; they were excluded by design. Patients with isoniazid resistance were likely to have streptomycin or ethambutol resistance. Table 3 provides the distribution of TB treatment outcomes by isoniazid susceptibility pattern. During the 6 months of follow-up, 797 (92.6%) of all patients were successfully treated (cured, (Table 4) .
Multivariate analysis (Table 4) showed that patients with isoniazid resistance were six times more likely to have poor treatment outcome (RR ¼ 6.0; 95% CI ¼ 1.9-18.7; P < 0.01). Overall, HIVinfected individuals were more likely to have unsuccessful treatment compared with HIV-uninfected individuals (P trend <0.01). However, HIV-coinfected TB patients not on ART during anti-TB treatment were three times more likely to die, fail TB therapy or be lost to follow-up from TB therapy (poor treatment outcome) compared with HIV-uninfected individuals (RR ¼ 3.1; 95% CI ¼ 1.5-6.2; P < 0.01). On the other hand, HIV-coinfected TB patients on ART had marginally increased risk of poor treatment outcome among TB/HIV-coinfected individuals on ART during TB treatment (RR ¼ 2.3; 95% CI ¼ 1.0-5.2; P ¼ 0.05). In a separate but similar model with the same covariates, we assessed the effect of isoniazid resistance on death alone. We found that male sex (RR ¼ 4.5; 95% CI ¼ 1.2-17.2; P ¼ 0.03), isoniazid resistance (RR ¼ 12.4; 95% CI ¼ 2.8-55.7; P ¼ 0.001) and HIV infection with ART (RR ¼ 4.4; 95% CI ¼ 1.3-15.4; P ¼ 0.02) or without ART (RR ¼ 4.4; 95% CI ¼ 1.5-14.7; P < 0.01) were independent predictors of death during 6 months of treatment with anti-TB drugs (data not shown).
Furthermore, there were no statistical differences between culture-positive TB patients who were included in the study (861) compared with culture-positive TB patients excluded from the study (504) with respect to mean age (33.5 versus 33.6 years; P ¼ 0.95, respectively), haemoglobin (10.4 versus 10.5 g/dL; P ¼ 0.75), mean albumin (31.1 versus 30.7 g/dL; P ¼ 0.42) and mean BMI (18.9 versus 18.9 kg/m 2 ; P ¼ 0.95). Moreover, the groups had similar proportions of men (67.2% versus 68.7%; P ¼ 0.57), HIV-infected patients (29.4% versus 30.1%; P ¼ 0.79), HIV-infected patients on ART during anti-TB therapy (13.7% versus 13.4%; P ¼ 0.93); HIV-infected patients not on ART (15.6% versus 16.6%; P ¼ 0.64), and HIV-coinfected patients in the two groups had similar CD4+ counts P ¼ 0.28. However, excluded patients were less likely to have treatment success (74.1% versus 92.6%), i.e. more likely to die during treatment (3.8% versus 2.9%) and more likely to move out of Dar es Salaam (17.7 versus 0%); P < 0.001. A similar observation was made when we compared patients included in this study (n ¼ 861) with all other TB patients with a positive Effects of isoniazid resistance on TB treatment outcomes, Tanzania JAC sputum smear recruited in the study, including culture-negative patients (n ¼ 944).
Discussion
We observed three main findings in the current study. First, background isoniazid resistance in the absence of MDR-TB is an important problem in Tanzania and it significantly affects TB treatment success rates. Second, about one in three TB patients had HIV coinfection. Third, HIV infection without concomitant ART and TB treatment significantly increased the risk of the combined outcome of death, treatment failure and default from TB therapy. The treatment success rate among new smear-positive TB patients found in our study (92.6%) is similar to the latest available national success rate (90%), 21 which is above the WHO treatment success target of 85% for national TB programmes. This underscores the rigorousness of TB treatment and control in Tanzania. However, notwithstanding the good treatment success, 7.4% of the patients recorded poor treatment outcomes, died or were lost from follow-up, or they failed their TB treatment. Addressing factors associated with the poor outcomes will further improve treatment success rates.
Our study found that isoniazid resistance adversely affected treatment outcomes in 17.3% of the patients; among these 13% died and 3.4% had treatment failure. A similar study conducted among patients with isoniazid-resistant TB in Taiwan showed almost similar treatment outcomes; among 17% of patients with unfavourable TB treatment outcomes, 14.2% died and 2.8% had treatment failure. 23 However, in that study the effect of HIV infection on treatment outcomes was not examined. 23 Isoniazid has been a strong pillar in the treatment of TB; loss of its activity against TB will not only affect treatment outcomes but also increases the risk of subsequent MDR-TB. 13, 24, 25 Treatment of MDR-TB is costly, takes a long time and usually has reduced success. [26] [27] [28] It is important, therefore, that efforts are made to preserve the activity of isoniazid, including monitoring the subtherapeutic drug level that may precede isoniazid resistance. 29 In a setting similar to Tanzania, where monitoring anti-TB drug resistance is not performed, cost-effective policies need to be put in place.
In agreement with the literature, HIV infection was associated with increased risk of poor TB treatment outcomes, particularly in TB/HIV-coinfected patients who have not been receiving concomitant ART during TB treatment. 30 This finding corroborates the recommendation for concomitant ART and anti-TB therapy. 30 Unlike previously published work, our study found no association between TB outcomes and smoking. 31 Cigarette smoke impairs the host's immune response to mycobacteria, including reduction of macrophage function and cytokine production. 32, 33 In our cohort, however, only 47 (5.6%) were currently smokers and therefore our study may not be powered to evaluate such an important factor in the presence of several co-factors, including isoniazid resistance, malnutrition, alcohol abuse and poverty. Therefore, the absence of a statistically significant association between smoking and TB treatment outcome in our study cannot be interpreted as evidence against the hypothesis of a relationship.
Our study has several strengths. The treatment success rate in our study population was similar to national TB treatment success, making our study findings representative and potentially extrapolatable to the country and probably other countries with a similar TB/HIV situation. Having a relatively large sample size, conducting the study at multiple sites and providing information about drug-resistant TB and HIV infection, which are major drivers of TB, make it very strong.
In Tanzania, CD4þ T lymphocyte enumeration is a standard of care for HIV-positive patients, but not for patients with TB. As a result, all of our TB-monoinfected patients did not have a CD4 count, making it difficult to evaluate this important immunological parameter in relation to TB outcomes among all TB patients (HIV negative and HIV positive), which may viewed as a limitation of this study. In addition, this analysis included 861 (63%) of all culture-confirmed TB patients. However, patients enrolled in this study showed similar laboratory parameters to patients excluded in terms of disease severity. However, since excluded patients were more likely to have an unsuccessful treatment outcome, it is likely that the magnitude of the associations found in this study may be underestimated.
In conclusion, isoniazid resistance and HIV infection appear to be independent risks for unsuccessful treatment outcome (death, treatment failure and loss to follow-up) among newly diagnosed patients with TB who present to TB services in Tanzania. Early laboratory detection of isoniazid resistance is important for commencing appropriate TB therapy and preventing subsequent development of MDR. Studies on the impact of background isoniazid resistance on the efficacy of isoniazid prophylaxis should be conducted. Strategies to minimize isoniazid resistance, as well as emphasis on dual treatment with ART and anti-TB therapy will improve TB treatment outcomes in TB/HIV-coinfected individuals.
